Best Cell Therapy CDMOs by Signal Score

← All Cell Therapy CDMOs Best Clean FDA History Commercial Scale

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

Cell therapy CDMOs manufacture living products — CAR-T, TCR, NK, and stem-cell therapies — where the process is the product. Autologous programs add patient-scheduling and chain-of-identity demands that allogeneic, batch-based programs avoid.

The right cell therapy CDMO depends on autologous vs allogeneic experience, vector sourcing, closed-system processing, and cold-chain logistics. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 11 NAI (no action), 12 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (22), Denmark (18), Germany (10), Ireland (6), Czechia (5).

Last updated 2026-06-24. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	91.7	98.7	7 insp · 11 GMP	Limited	0 programs
2	BMS Bristol Myers Squibb (CGT Mfg) Bothell, WA · Warren, NJ	90.8	97.0	5 insp · 2 GMP	—	576 programs
3	COH City of Hope (T Cell Manufacturing) Duarte, CA	83.8	96.8	3 insp · 0 GMP	—	207 programs
4	WB2 WuXi Biologics Shanghai, CN · Wuxi, CN	83.7	100.0	0 insp · 4 GMP	—	0 programs
5	MN Minaris Advanced Therapies Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP	83.5	100.0	1 insp · 6 GMP	Limited	0 programs
6	MK Merck KGaA / MilliporeSigma (CDMO) Darmstadt, DE · St. Louis, MO	81.8	98.6	2 insp · 2 GMP	—	22 programs
7	SC SCTbio Prague, Czech Republic	81.6	100.0	0 insp · 5 GMP	—	0 programs
8	EF Eurofins CDMO Planegg, DE · San Diego, CA	81.6	100.0	4 insp · 0 GMP	—	0 programs
9	DH Danaher (CGT Portfolio) Washington, DC	81.5	—	—	—	0 programs
10	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	80.6	99.9	1 insp · 23 GMP	Available	2 programs

How we score CDMOs →

What to evaluate in a Cell Therapy CDMO

Autologous vs allogeneic

Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.

Vector & raw materials

Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.

Closed-system & cleanrooms

Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.

Cold chain & logistics

Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.

Cell Therapy CDMOs — Frequently Asked Questions

Who are the top Cell Therapy CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Cell Therapy CDMOs include Charles River Laboratories, Bristol Myers Squibb (CGT Mfg), City of Hope (T Cell Manufacturing). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Cell Therapy CDMOs have FDA inspection records?

CDMO Signal tracks 7 Cell Therapy CDMOs with FDA inspection records and 53 EMA/MHRA GMP certificates across the group.

What should I look for in a cell therapy CDMO?

Match the CDMO to your model: autologous needs chain-of-identity and fast turnaround; allogeneic needs scalable batch processing. Confirm vector sourcing, closed-system processing, cold-chain logistics, and a clean FDA and EMA/MHRA record.

Do cell therapy CDMOs make their own viral vectors?

Some do in-house; others coordinate an external vector supplier. In-house vector can shorten timelines and simplify supply, but a strong external partner is common. Check each profile's modality coverage above.

Related modalities

Lentiviral Vector CDMOs CAR-T CDMOs Gene Editing CDMOs

Other Modalities

AAV CAR-T Lentiviral mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC